GlobeNewswire Inc | Nov 30, 2020 08:00AM EST

November 30, 2020

WESTLAKE VILLAGE, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Sabrina Kay Ed.D. has been appointed to its Board of Directors, effectiveDecember 1, 2020.Dr. Kay will also serve as a member of the Audit Committee of the Board. A serial entrepreneur, tech educator, fashion designer, philanthropist, and public speaker, Dr. Kaybrings toMannKinda wealth of experience in marketing, human capital development, finance and executive leadership.

We are excited to welcomeDr. Kayand her years of invaluable leadership to our Board of Directors, saidKent Kresa, Chairman of the Board. Her entrepreneurial vision will be a critical asset forMannKindas the company continues to evolve and the pipeline expands. Dr. Kay has a successful track record in launching and leading a variety of companies, and will add a fresh and diverse perspective as we continue to pursue our mission to give people control of their health and the freedom to live life.

Currently, Dr. Kay serves as Founder and CEO of Fremont Private Investments, where she has led the operations and exits of several companies including The Art Institute of Hollywood (sold to NASDAQ: EDMC), Premier Business Bank (sold to NASDAQ: FFWM), Fashion Umbrella, Fremont College, and Dale Carnegie of Los Angeles.

In addition to her success in the business world, Dr. Kay is a philanthropist, having served onmore than 30 charitable and civic boards. She is chairman of After-School All-Stars Los Angeles, and a board member of the Los Angeles Sports and Entertainment Commission, Petersen Automotive Museum, Portal Schools, the Leadership Council of International Medical Corps LeadershipCouncil, and the Board of Leaders of USC Marshall School. Dr. Kay has also chaired and spoken atnumerous tech, education, business, and leadership conferences, and taught entrepreneurship programsat various universities.

Dr. Kays achievements have been recognized with numerous awards, including the Education Awardfrom After-School All-Stars and theHumanitarian Award from International Medical Corps. She was named Woman of the Year by theCalifornia Legislature, Rising Asian Woman by the World Affairs Council, and was a finalist forEntrepreneur of the Year by Ernst & Young.

Dr. Kay received her joint doctorate degree in Work-based Learning Leadership from the University of Pennsylvania. She holds an MBA from theUniversity of Southern California and a Master of Science degree in education from theUniversity of Pennsylvania.

With the addition ofDr. Kay, there are nine members of the MannKind Board of Directors.

AboutMannKind Corporation

MannKind Corporation(NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases.MannKindis currently commercializing Afrezza (insulin human) Inhalation Powder, the Companys first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin inthe United States, where it is available by prescription from pharmacies nationwide.MannKindis headquartered inWestlake Village, California, and has a state-of-the art manufacturing facility inDanbury, Connecticut. The Company also employs field sales and medical representatives across theU.S.For further information, visitwww.mannkindcorp.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based uponMannKind'scurrent expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed inMannKind'sfilings with theSEC. For a discussion of these and other factors, please refer to MannKinds annual report on Form 10-K for the year endedDecember 31, 2019 as well as MannKinds other filings with theSEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, andMannKindundertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Company Contact: 818-661-5000ir@mannkindcorp.com